This substudy aims to answer the question whether ceftriaxone administered 2g once a day is non-inferior to administering (flu)cloxacillin by infusion in patients with Staphylococcus aureus bacteraemia who are stable at D7 or D14 post-infection.
SNAP Trial
Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia
Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.
Pilot study for real-time sequencing of Staphylococcus aureus bloodstream isolates
Using a validated penicillin allergy risk prediction tool (Pen-FAST) in patients with a low risk penicillin allergy
Immunopathogenesis and pharmacogenomics of severe antibiotic hypersensitivity
